专家小组建议:在MASH/NASH合并中度至非肝硬化晚期纤维化患者中起始与监测resmetirom的临床实践应用
代谢功能障碍相关脂肪性肝病在欧美约每4人中有1人患病,部分进展为代谢功能障碍相关脂肪性肝炎(MASH)。美国食品药品监督管理局(FDA)近期附条件批准resmetirom用于治疗中度或晚期MASH,目标人群为MASH合并纤维化2期或3期患者。本文基于现有文献,探讨如何无创识别适合resmetirom治疗的患者,并提出停药标准。
要点
- resmetirom经FDA附条件批准用于MASH合并纤维化2期或3期患者。
- 需无创识别纤维化2-3期患者并排除更晚期疾病患者。
- 专家小组提出resmetirom的起始与监测及停药标准。
核心结论
- resmetirom为MASH合并纤维化2期或3期患者提供了期待已久的治疗选择,但需解决无创识别目标人群和排除更晚期患者等挑战,并提出了停药标准。
研究设计与样本
- 专家小组基于现有文献提出临床实践建议。
主要发现
- 代谢功能障碍相关脂肪性肝病在美國和西欧影响约四分之一人群,其中重要比例发展为MASH。
- MASH导致的肝硬化是肝移植的主要指征和肝细胞癌的最常见病因。
- 此前MASH尚无特异性药物治疗。
关键数值与推荐
- resmetirom的目标人群为MASH合并纤维化2期或3期患者。
- 需无创识别纤维化2-3期患者,并排除更晚期疾病患者直至获得进一步数据。
临床怎么用
- 专家小组建议在MASH合并纤维化2期或3期患者中起始resmetirom治疗,并监测及依据标准停药。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metabolic dysfunction-associated steatotic liver disease affects 1 in 4 people in the United States and western Europe, with an important proportion developing metabolic dysfunction-associated steatohepatitis (MASH), the progressive subtype of metabolic dysfunction-associated steatotic liver disease. Cirrhosis caused by MASH is a leading indication for liver transplantation and the most common cause of hepatocellular carcinoma. Hitherto, there have been no specific pharmacotherapies for MASH. The recent conditional approval by the Food and Drug Administration of resmetirom for the treatment of moderate or advanced MASH presents a much-anticipated therapeutic option for patients with noncirrhotic advanced MASH. Specifically, the intended population for resmetirom are patients with MASH and fibrosis stages 2 or 3. The approval of resmetirom also presents important challenges, including how to noninvasively identify patients with fibrosis stages 2-3, and how to exclude patients with more advanced disease who should not be treated until further data emerge on the use of resmetirom in this population. Herein we consider the available literature with regard to identifying the intended population for treatment with resmetirom and in proposing criteria for stopping treatment.
引用
- Noureddin M, Charlton MR, Harrison SA, et al. Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis. Clin Gastroenterol Hepatol. 2024. PMID: 39038768. doi:10.1016/j.cgh.2024.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。